

Rhodium-Catalyzed Asymmetric Arylation of Cyclic *N*-Sulfonyl Aryl Alkyl Ketimines: Efficient Access to Highly Enantioenriched α -Tertiary Amines

Tao Jiang, Zheng Wang, and Ming-Hua Xu*

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

(5) Supporting Information

ABSTRACT: A simple catalyst system of Rh(I)/sulfur-olefin with exceptional catalytic performance has been developed for the highly enantioselective arylation of cyclic *N*-sulfonyl aryl alkyl ketimines with arylboroxines/arylboronic acids. Optically active α -arylalkyl-substituted benzosultams and benzosulfamidates which are generally difficult to obtain were easily prepared with excellent stereocontrol (up to 99.9% ee). The synthetic utility of the approach was demonstrated by the facile construction of NMDA antagonist FR115427 and benzoxazinone derivatives. This protocol offers new opportunities for the efficient synthesis of diverse chiral α -tertiary amines.

ransition-metal-catalyzed asymmetric addition of organo-I metallic reagents to imines is a powerful strategy for the straightforward synthesis of chiral methylamines^{1,2} that are an important motif present in many natural products, biologically active compounds, and functional organic molecules. Rhodium and palladium catalysis using stable organoboron reagents has received particular interest in recent years.² While asymmetric variants of the addition of organoboron reagents to aldimines have been studied intensively,³ efficient enantioselective access to the corresponding α -tertiary amines is often problematic because of the employment of relatively less reactive ketimines and the difficulties encountered in the control of stereofacial differentiation. Successful examples of asymmetric addition to ketimines are therefore rare.^{4–6} In 2010, an important advance involving the enantioselective addition of sodium tetraarylborates to *N*-tosyl ketimines with Rh/diene catalysts was achieved by Shintani and Hayashi.^{4b} Since then, several new developments in this area have emerged; however, achieving excellent enantiocontrol with a broad substrate scope still represents a challenging task.

Optically active sultams and sulfamidates bearing an α stereogenic center in the amine moiety are two intriguing classes of cyclic amines. We^{5a,b} and other groups^{3i,4d,f,g} have recently demonstrated that the catalytic asymmetric addition of organoboron reagents to cyclic *N*-sulfonyl imines is an efficient method for the synthesis of such compounds. Most notably, high enantioselectivities were recently obtained in the addition of arylboronic acids to alkyl-substituted cyclic *N*-sulfonyl ketimines under palladium catalysis by Zhang^{6a} (eq 1) and Hayashi/Lu^{6b} (eq 2) using chiral pyridine-oxazoline and phosphine-oxazoline ligands, respectively, affording enantioenriched benzosultams and benzosulfamidates. In continuation of our own exploration



Recent work by Zhang (in 2013) and Hayashi/Lu (in 2014):



of Rh/SOL-catalyzed asymmetric addition of diverse imines and carbonyl compounds,^{5d} we describe herein our development of an elegant catalytic system that exhibits remarkable selectivity in the asymmetric arylation of cyclic *N*-sulfonyl aryl alkyl ketimines, allowing the construction of both α -arylalkyl-substituted benzosultams and benzosulfamidates with excellent enantiose-lectivities (eq 3).

Initially we chose methyl substituted five-membered N-sulfonyl imine 1a as the substrate and commenced the reaction with 4-methoxyphenylboronic acid (2a) using our previously developed sulfur-olefin ligands (SOLs) L1–L3 in KOH (1.5 M)/toluene at 60 °C in the presence of 1.5 mol % of

Received: December 8, 2014 Published: January 21, 2015 $[Rh(COE)_2Cl]_2$ (Table 1, entries 1–3). As expected, these Rh(I)/SOLs were found to be able to catalyze the reaction.

Table 1. Conditions Optimization for Addition to Ketimine 1a^a [Rh(COE)2CI]2/L 4-MeOPh[B] base, solvent, 60 °C 2 4-MeOPh L3 R = Ph L1 L2 L4 R = 2-Naphthyl L5 R = 1-Naphthyl yield (%)^b ee (%)^c entry ligand base (aq) solvent 1^d L1 кон 13 40 toluene 2^d L2 кон toluene 50 81 3^d L3 кон 59 93 toluene L3 кон 99 95 4 toluene 5 14 кон 99 96 toluene 97 6 L5 KOH 99 toluene 97 7 L5 KF toluene 88 K₂CO₃ 97 8 L5 toluene 99 9 L5 K₃PO₄ toluene 95 97 10 L5 кон 98 dioxane 58 L5 кон THF 60 98 11 12 L.5 кон DCE 99 98 кон 13 L5 DCE 89 98

^{*a*}Conditions: 1a (0.20 mmol), 2 (boroxine, 1.5 equiv), [Rh- $(COE)_2CI]_2$ (1.5 mol %), ligand (3.3 mol %), and base (1.5 M, 0.60 mmol) in 1.0 mL of solvent at 60 °C for 12 h unless otherwise noted. ^{*b*}Isolated yields. ^{*c*}Determined by chiral HPLC analysis. ^{*d*}4-Methoxyphenylboronic acid (2 equiv) was used. ^{*e*}Reaction was performed at rt.

Among them, L3 exhibited promising enantioselectivity, affording the desired addition product in 59% yield and 93% ee (entry 3). Gratifyingly, when 4-methoxyphenylboroxine (2b) was employed instead of 4-methoxyphenylboronic acid, the reaction proceeded with great efficiency and high enantioselectivity (entry 4). Further investigation on ligands disclosed that L5 bearing a more bulky R (1-naphthyl) group gave the highest enantioselectivity while maintaining the same excellent activity (entry 6). Varying the base did not furnish better results (entries 7–9). Interestingly, under otherwise identical conditions, the use of 1,2-dichloroethane as solvent led to even slightly improved enantioselection (entry 12). In this optimal catalytic system, it is noted that comparable enantioselectivity can be obtained when the reaction was performed at ambient temperature (entry 13).

With the optimized conditions, we examined the scope of the reaction (Table 2). A wide variety of arylboroxines having electron-donating or -withdrawing groups on the phenyl ring reacted smoothly with cyclic *N*-sulfonyl ketimines 1, providing the addition products α -arylalkyl-substituted benzosultams (3) uniformly in high yields and with excellent enantioselectivities (90–99% ee). Of particular note is that the reaction can be effective with a sterically hindered boron reagent bearing an ortho-substituent such as 2-methylphenylboroxine, albeit with a decreased yield (entries 6, 11, 15, 19). Moreover, the reaction enantioselectivity is generally not affected by the alkyl substitution of imine substrates. The aliphatic substituents

Table 2. Rhodium-Catalyzed Asymmetric Arylation of Cyclic Ketimines 1^a

	N +	$(ArBO)_3 = \frac{[Rh(CC)]}{KOH(1.5)}$	DE) ₂ Cl] ₂ /L	5 30 °C	NH
	alkyl	2	,, = = =, .	Ai	alkyl
	1			3	1
entry	v alkyl	Ar	3	yield ^b (%)	$ee^{c,a}$ (%)
1	Me	4-MeOC ₆ H ₄	3a	99	98
2	Me	C_6H_5	3b	99	98
3	Me	$4-MeC_6H_4$	3c	99	98
4	Me	$4-ClC_6H_4$	3d	99	98
5	Me	$3-MeOC_6H_4$	3e	88	98
6	Me	$2-MeC_6H_4$	3f	66	90
7	Et	4-MeOC ₆ H ₄	3g	97	99
8	Et	C_6H_5	3h	95	99
9	Et	$4-ClC_6H_4$	3i	99	99
10	Et	$3-MeOC_6H_4$	3j	99	98
11	Et	$2-MeC_6H_4$	3k	77	99
12	"Bu	C ₆ H ₅	31	99	99
13	"Bu	$4-ClC_6H_4$	3m	99	99
14	"Bu	3-MeOC ₆ H ₄	3n	91	99
15	"Bu	$2-MeC_6H_4$	30	41	92
16	Bn	4-MeOC ₆ H ₄	3p	99	99
17	Bn	C ₆ H ₅	3q	99	99
18	Bn	3-MeOC ₆ H ₄	3r	99	98
19	Bn	$2-MeC_6H_4$	3s	66	99
20	ⁱ Pr	4-MeOC ₆ H ₄	3t	98	99
21	Cyclopentyl	4-MeOC ₆ H ₄	3u	99	98
22	Су	C_6H_5	3v	99	99
23	Су	4-ClC ₆ H ₄	3w	99	99
24	Су	3-MeOC ₆ H ₄	3x	99	99
25	Су	$4-FC_6H_4$	3y	97	99

^{*a*}Conditions: **1** (0.20 mmol), **2** (1.5 equiv), $[Rh(COE)_2Cl]_2$ (1.5 mol %), ligand (3.3 mol %), and KOH (1.5 M, 3.0 equiv) in 1.0 mL of DCE at 60 °C for 12 h. ^{*b*}Isolated yields. ^{*c*}Determined by HPLC. ^{*d*}The absolute stereochemistry was determined by comparing the $[\alpha]_D$ with known data.^{6a}

could include a broad range of groups including methyl, ethyl, butyl, benzyl, isopropyl, cyclopentyl, and cyclohexyl. To our knowledge, these results are among the best in the asymmetric addition of organoboron reagents to alkyl-substituted cyclic *N*-sulfonyl ketimines.

Having established the highly enantioselective arylation of five-membered N-sulfonyl ketimines, we turned our attention to six-membered ring imines for a similar addition, which could lead to chiral benzosulfamidates. In general, six-membered cyclic imines are considered to be less reactive than five-membered ones. To test if the aforementioned conditions are applicable, we conducted the reaction with ketimine 4a bearing a methyl group attached to the imine carbon as the substrate. To our disappointment, only a trace amount of product formation was observed (Table 3, entry 1). After some careful experiments, we were delighted to find that the reaction can be promoted at 80 °C in tert-amyl alcohol/dioxane in the presence of solid K₂CO₃ (3 equiv), giving a 65% isolated yield of the expected adduct benzosulfamidate 5a with an extremely high enantioselectivity (99.7% ee) (entry 4). Interestingly, the use of 4-methoxyphenyl boronic acid (2 equiv) in combination with KHF_2 (1.5 M) in toluene at 80 °C produced 5a in an improved yield (75%) with equally high enantioselectivity (99.9% ee) (entry 5). While the

4a^{*a*}

 6^h

ArB(OH)

89

99.9



^aConditions: 4a (0.10 mmol), 2 (2.0 equiv), [Rh(COE)₂Cl]₂ (1.5 mol %), ligand (3.3 mol %), and salt (3.0 equiv) in 1.5 mL of solvent at 60 °C for 24 h unless otherwise noted. ${}^{b}Ar = 4$ -MeOPh. ^cIsolated yields. ^dDetermined by HPLC. ^e0.67 equiv. ^f3 equiv. ^g80 °C. ^h100 °C.

KHF₂ (1.5 M), toluene

reaction was carried out with 3 equiv of boronic acid at 100 °C, the corresponding 5a can be obtained in both very good yield (89%) and enantioselectivity (99.9% ee) (entry 6).

Under the newly optimized reaction conditions, the substrate scope was evaluated. As summarized in Table 4, all excellent



0,0			0 <u>_</u> 0			
O´ ^S `N ↓			[Rh(COE)2CI]2/L	5 0 ^{-S} 1	o∕ ^s `nh ↓ ↓	
	alkyl	2 AID(01)2	KHF ₂ (1.5 M)		Ar Ar	
	4		toluene,100 °C		5	
ontra	allari	Δ	5	$riald^{b}(\%)$	$c_{c,d}(0/2)$	
entry	y aikyi	Л	3	yield (%)	ee (%)	
1	Me	4-MeOC ₆ H ₄	5a	89	99.9	
2	Me	$3-MeOC_6H_4$	5b	75	99.8	
3	Me	2-MeOC ₆ H ₄	5c	17	99.3	
4	Me	4-MeC ₆ H ₄	5d	79	99.8	
5	Me	C ₆ H ₅	5e	76	99.8	
6	Me	3-MeC ₆ H ₄	5f	63	97.6	
7	Me	$4-FC_6H_4$	5g	47	99.5	
8	Me	4-MOMOC ₆ H	4 5h	75	99.8	
9	Me	2-naphthyl	5i	62	99.9	
10	Me	3-thienyl	5j	74	99.6	
11	Me	2-furanyl	5k	49	98.5	
12	Et	4-MeOC ₆ H ₄	51	96	99.6	
13	Et	C ₆ H ₅	5m	82	99.8	
14	"Bu	4-MeOC ₆ H ₄	5n	78	99.9	
15	"Bu	C ₆ H ₅	50	72	99.9	

^aConditions: 4 (0.10 mmol), 2 (3.0 equiv), [Rh(COE)₂Cl]₂ (1.5 mol %), ligand (3.3 mol %), and KHF2 (1.5 M, 3.0 equiv) in 1.5 mL of toluene at 100 °C for 24 h. ^bIsolated yields. ^cDetermined by HPLC. d The absolute stereochemistry was determined by comparing the $[\alpha]_{\rm D}$ with known data.^{6b}

enantioselectivities (97.6-99.9% ee) were observed with a wide range of arylboronic acids regardless of the substitution pattern (entries 1-9), although sterically hindered 2-methoxyphenylboronic acid afforded a low yield (entry 3). The reaction also proceeded with great enantiomeric control when heteroboronic acids such as 3-thienyl and 2-furanyl boronic acids were employed (entries 10, 11). In addition to methyl-substituted ketimine 4a, those bearing ethyl and butyl were also suitable

substrates for this arylation, giving the corresponding enantiomerically pure benzosulfamidate products 51-50 (entries 12-15). Using the same conditions, we further examined the addition of 4-methylphenylboronic acid to phenyl-substituted ketimine 4^{5a} and found that a relatively high enantioselectivity (91% ee) could be obtained, but the yield was not ideal (38%).

To highlight the synthetic utility, we have applied this methodology in the synthesis of a series of biologically interesting compounds. For example, treatment of benzosultam 3b with ethyl bromoacetate followed by Friedel-Crafts cyclization furnished the tetracyclic sulfonamide intermediate 7 bearing a tetrasubstituted carbon stereogenic center on the ring. Subsequently, compound 7 was converted to 8 first and then underwent sultam ring cleavage under the conditions of sodium naphthalenide, providing an efficient asymmetric synthesis of FR115427,⁷ a tetrahydroisoquinoline compound that was developed as an NMDA antagonist to prevent ischemia-induced neuronal degeneration (Scheme 1a). In the other case, ring





opening of benzosulfamidate 6a with LiAlH₄ gave the corresponding phenolic methylamine intermediate 9, which was subjected to triphosgene/Et₃N to produce benzoxazinone derivative 10 without losing optical purity (Scheme 1b). The benzoxazinone compounds have been reported with PKM2 activities to treat neoplastic disorders.⁸

In summary, we have developed an efficient rhodiumcatalyzed asymmetric arylation process. Challenging cyclic Nsulfonyl aryl alkyl ketimines reacted smoothly with organoboron reagents in the presence of a simple chiral sulfur-olefin ligand to give α -arylalkyl-substituted benzosultams and benzosulfamidates with excellent stereocontrol (up to 99.9% ee). In contrast to known reports,⁶ this method is quite advantageous in terms of simplicity of the catalytic system. It is also noteworthy that the results particularly for benzosultams are superior. Further studies of the synthetic utilities of this protocol reveal it to be a promising method for the synthesis of many other valuable amine derivatives.

ASSOCIATED CONTENT

Supporting Information

Experimental procedures and product characterization. This material is available free of charge via the Internet at http://pubs. acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: xumh@simm.ac.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful for financial support from the National Natural Science Foundation of China (21325209, 21472205) and the Shanghai Municipal Committee of Science and Technology (14XD1404400).

REFERENCES

(1) For selected reviews, see: (a) Friestad, G. K.; Mathies, A. K. *Tetrahedron* **2007**, *63*, 2541. (b) Shibasaki, M.; Kanai, M. *Chem. Rev.* **2008**, *108*, 2853. (c) Yamada, K.; Tomioka, K. *Chem. Rev.* **2008**, *108*, 2874. (d) Kobayashi, S.; Mori, Y.; Fossey, J. S.; Salter, M. M. *Chem. Rev.* **2011**, *111*, 2626.

(2) For a review, see: Marques, C. S.; Burke, A. J. *ChemCatChem* **2011**, 3, 635.

(3) For selected examples, see: (a) Kuriyama, M.; Soeta, T.; Hao, X. Y.; Chen, O.; Tomioka, K. J. Am. Chem. Soc. **2004**, 126, 8128. (b) Otomaru, Y.; Tokunaga, N.; Shintani, R.; Hayashi, T. Org. Lett. **2005**, 7, 307. (c) Duan, H.-F.; Jia, Y.-X.; Wang, L.-X.; Zhou, Q.-L. Org. Lett. **2006**, 8, 2567. (d) Jagt, R. B. C.; Toullec, P. Y.; Geerdink, D.; de Vries, J. G.; Feringa, B. L.; Minnaard, A. J. Angew. Chem., Int. Ed. **2006**, 45, 2789. (e) Wang, Z.-Q.; Feng, C.-G.; Xu, M.-H.; Lin, G.-Q. J. Am. Chem. Soc. **2007**, 129, 5336. (f) Okamoto, K.; Hayashi, T.; Rawal, V. H. Chem. Commun. **2009**, 4815. (g) Yang, H.-Y.; Xu, M.-H. Chem. Commun. **2010**, 9223. (h) Cui, Z.; Yu, H.-J.; Yang, R.-F.; Gao, W.-Y.; Feng, C.-G.; Lin, G.-Q. J. Am. Chem. Soc. **2011**, 133, 12394. (i) Luo, Y.-F.; Hepburn, H. B.; Chotsaeng, N.; Lam, H. W. Angew. Chem., Int. Ed. **2012**, 51, 8309. (j) Chen, C.-C.; Gopula, B.; Syu, J.-F.; Pan, J.-H.; Kuo, T.-S.; Wu, P.-Y.; Henschke, J. P.; Wu, H.-L. J. Org. Chem. **2014**, 79, 8077.

(4) For pioneering work on the asymmetric addition of ketimines with allylborate under copper catalysis, see: (a) Wada, R.; Shibuguchi, T.; Makino, S.; Oisaki, K.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2006, 128, 7687. For rhodium-catalyzed additions, see: (b) Shintani, R.; Takeda, M.; Tsuji, T.; Hayashi, T. J. Am. Chem. Soc. 2010, 132, 13168. (c) Shintani, R.; Takeda, M.; Soh, Y.-T.; Ito, T.; Hayashi, T. Org. Lett. 2011, 13, 2977. (d) Nishimura, T.; Noishiki, A.; Tsui, G. C.; Hayashi, T. J. Am. Chem. Soc. 2012, 134, 5056. (e) Nishimura, T.; Ebe, Y.; Fujimoto, H.; Hayashi, T. Chem. Commun. 2013, 49, 5504. (f) Nishimura, T.; Noishiki, A.; Ebe, Y.; Hayashi, T. Angew. Chem., Int. Ed. 2013, 52, 1777. (g) Hepburn, H. B.; Lam, H. W. Angew. Chem., Int. Ed. 2014, 53, 11605. (h) Chen, Y.-J.; Chen, Y.-H.; Feng, C.-G.; Lin, G.-Q. Org. Lett. 2014, 16, 3400.

(5) (a) Wang, H.; Jiang, T.; Xu, M.-H. *J. Am. Chem. Soc.* 2013, *135*, 971.
(b) Wang, H.; Xu, M.-H. *Synthesis* 2013, 2125. (c) Wang, H.; Li, Y.; Xu, M.-H. *Org. Lett.* 2014, *16*, 3962. For a focus review on sulfur-olefins, see:
(d) Li, Y.; Xu, M.-H. *Chem. Commun.* 2014, *50*, 3771.

(6) (a) Yang, G.; Zhang, W. Angew. Chem., Int. Ed. 2013, 52, 7540.
(b) Jiang, C.-H.; Lu, Y.-X.; Hayashi, T. Angew. Chem., Int. Ed. 2014, 53, 9936.

(7) (a) Takasugi, H.; Kuno, A.; Ohkubo, M. U.S. Patent 5059608, 1991. (b) Ohkubo, M.; Kuno, A.; Katsuta, K.; Ueda, Y.; Shirakawa, K.; Nakanishi, H.; Nakanishi, I.; Kinoshita, T.; Takasugi, H. *Chem. Pharm. Bull.* **1996**, *44*, 95. (c) Ueda, Y.; Nakanishi, H.; Yoshida, K. *Life Sci.* **1999**, 65, 1477.

(8) Salituro, F. G.; Saunders, J. O. WO 2012/088314A1, 2012.